811 · Life Sciences

811 is a lifesciences research company.

We develop problem-first scientific approaches to identify and test signals hidden within complex biological and clinical data.

How we begin

We define the problem before choosing the tool.

Every project begins by defining the decision that needs support, the available evidence, and what would count as a useful, testable result.

How we work with evidence

We structure fragmented observations into testable patterns.

Clinical and biological findings often carry limited meaning in isolation. We evaluate them together to investigate relationships that may otherwise remain hidden.

How we establish confidence

A pattern becomes useful only when it can be challenged.

We evaluate each approach against real data, define its evidence boundary, and report uncertainty instead of presenting an unvalidated result as fact.

How the work becomes useful

We design findings to support expert decisions.

Our methods are intended for research and decision support. They organize relevant evidence for the people responsible for interpreting it; they do not replace scientific or clinical judgment.

Our first field of work

We are beginning with rare disease.

We are developing predictive research models that evaluate combinations of clinical findings for risk prioritization and earlier specialist referral. Validation against real clinical data is underway.

Progressing

Explore our rare-disease work

This page's opening sequence needs WebGL2, which this browser does not offer. Everything the sequence narrates is written out in full below.

I / Current work

What are we working on today?

We are developing predictive research models that evaluate combinations of clinical findings, so that the cases most in need of attention can be prioritized and referred to a specialist earlier.

Progressing

The responsibility for interpretation remains with the scientific and clinical experts.

II / First challenge

Our first challenge: rare disease.

Rare-disease pathways concentrate the difficulty: evidence is sparse, histories are fragmented across specialties, and a missed signal costs years. It is where a problem-first method is tested hardest.

Progressing

Predictive research models that evaluate combinations of clinical findings for risk prioritization and earlier specialist referral.

Active research

Structured research workflows that relate phenotype patterns to fragmented evidence across separate records.

Hypothesis

Earlier visibility may help teams decide which questions to investigate first. This is an open research question, not a demonstrated outcome.

Explore our rare-disease work→

III / Method

The problem determines the tool.

We do not begin with a fixed model or a predetermined technology. We begin by defining the decision that needs support and what would count as a useful, testable result.

Define the problem

Name the decision, the available evidence, and the result that would actually be useful.

Structure and challenge the signal

Bring fragmented observations into a testable pattern, then evaluate it against real data and report its uncertainty.

Support the decision

Return findings in a form the responsible expert can interpret, question, and act on.

Read our approach→

IV / Horizon

Rare disease is the beginning.

Over the long term we intend to apply the same problem-first method to wider lifesciences questions. That is a direction of work, not a description of what has been validated today.

Read our vision→

Collaboration

Bring us the question that is still difficult to see.

We work with a small number of research and clinical groups on consequential questions where the evidence already exists but the pattern does not yet.

Start a Conversation

See. Understand. Transform.